~~<i id='9EA7513497'><strike id='9EA7513497'><tt id='9EA7513497'><pre id='9EA7513497'></pre></tt></strike></i>~~

Home» explore» explore

explore

author：Wikipedia 2025-10-01 22:38:54 Page View：4619

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Rock icon Freddie Mercury pre
Next article： As demand for Covid shots wanes, Moderna seeks its next success

leisure time

Virginia high school admissions case could be legal follow

3:24DemonstratorsprotestoutsideoftheSupremeCourtinWashington,Thursday,June29,2023,aftertheSupremeCou

Teen charged with murder as hate crime in killing of NYC dancer O'Shae Sibley: Sources

3:10O'ShaeSibleyinanundatedportrait.CourtesyKemarJewelAteenagerhasbeenchargedwithmurderasahatecrimei

Sports medicine is finally prioritizing gender equality

MollyFergusonforSTATWhencyclistAlisonTetrickjoinedthesport’sprofessionalranks,shereceivedtheperkstha

2 million sign

2:55MarkZuckerberg,chiefexecutiveofficerandfounderofFacebookInc.,speaksduringtheSiliconSlopesTechSum

WSS

explore

explore

focus

leisure time

2 million sign